SPRB.NASDAQSpruce Biosciences, INC

Form 4: Spruce Biosciences CEO Reports RSU Vesting and New Grant

Sentiment:

Insider Transaction Report

📋All filings for Spruce Biosciences, INC
🔒Login to Follow

Spruce Biosciences CEO Javier Szwarcberg reported the vesting of restricted stock units and subsequent tax-related share dispositions, alongside a new RSU grant.

Summary

  • Spruce Biosciences, Inc. CEO Javier B. Szwarcberg reported transactions involving common stock and Restricted Stock Units (RSUs).
  • On December 10, 2025, 1,196 shares of common stock vested from an RSU grant made on March 14, 2024, which was tied to a clinical development objective.
  • Following this vesting, 428 shares were disposed of at a price of $85.67 to cover tax obligations, resulting in a net issuance of 768 shares.
  • On December 11, 2025, an additional 4,950 shares of common stock vested from a separate RSU grant.
  • Concurrently, 2,194 shares were disposed of at a price of $88.41 for tax withholding, leading to a net issuance of 2,756 shares.
  • A new grant of 19,800 Restricted Stock Units (RSUs) was also reported on December 11, 2025, with 25% vesting immediately upon grant.
  • Following these transactions, the CEO's direct beneficial ownership of common stock is 12,998 shares, and 14,850 derivative Restricted Stock Units remain beneficially owned.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled executive compensation events (RSU vesting and tax withholding) and a new RSU grant. These are neutral events that do not inherently indicate positive or negative company performance or outlook.

Positives

  • The vesting of Restricted Stock Units indicates the CEO's continued service and achievement of specified objectives, aligning management interests with shareholders.
  • A new grant of 19,800 RSUs demonstrates ongoing compensation and retention of the Chief Executive Officer.

Negatives

  • A total of 2,622 shares (428 + 2,194) were disposed of to cover tax liabilities, reducing the CEO's direct share ownership.

Future Outlook

Future vesting events for the CEO's Restricted Stock Units are scheduled for December 15, 2026, December 15, 2027, and December 15, 2028, contingent upon continuous service.

Industry Context

This filing reflects routine executive equity compensation practices common across the biotechnology and pharmaceutical industries, where stock-based incentives are used to align management's long-term interests with company performance and shareholder value.

Related Party Transactions

  • Vesting of Restricted Stock Units and subsequent share dispositions for tax withholding for CEO Javier B. Szwarcberg, representing executive compensation.

Stakeholder Impact

  • Shareholders: Minor dilution from the issuance of shares upon RSU vesting, but also indicates alignment of CEO's interests with long-term company performance.
  • Employees: Reflects standard executive compensation practices, potentially influencing broader compensation strategies.

Next Steps

  • Continued vesting of the CEO's RSU grants on scheduled future dates (December 15, 2026, 2027, 2028), subject to continuous service.

Key Dates

DateDescription
03/14/2024Date of grant for 4,784 RSUs, with 25% vesting on December 10, 2025, and subsequent anniversaries of a clinical development objective achievement.
12/10/2025Transaction date for the vesting of 1,196 RSUs and disposition of 428 shares for tax withholding.
12/11/2025Transaction date for the vesting of 4,950 RSUs, disposition of 2,194 shares for tax withholding, and a new grant of 19,800 RSUs.
12/12/2025Filing date of the Form 4.
12/15/2026Future vesting date for 25% of the 19,800 RSU grant, subject to continuous service.
12/15/2027Future vesting date for 25% of the 19,800 RSU grant, subject to continuous service.
12/15/2028Future vesting date for 25% of the 19,800 RSU grant, subject to continuous service.

Recommendation

hold

This Form 4 filing details routine, pre-scheduled executive compensation events (RSU vesting and tax-related share dispositions) and a new RSU grant. Such transactions are generally expected and do not typically provide new fundamental information that would alter an investment thesis. Therefore, a 'hold' recommendation is appropriate, as the filing does not present a compelling reason to change an existing position based solely on these insider transactions.

Keywords

Spruce Biosciences, SPRB, Form 4, Insider Transaction, Restricted Stock Units, RSU, CEO, Equity Compensation, Stock Vesting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.